Molecular Assemblies was featured in Nature Biotechnology in an article entitled, “DNA writing technologies moving toward synthetic genomes.”
The ability for biopharmaceutical companies to generate long, pure oligonucleotides that are not only accurate, but cost effective and efficient, is essential for innovation. Molecular Assemblies’ Fully Enzymatic Synthesis (FES™) technology fulfills this need with an updated, proprietary terminal deoxynucleotide transferase (TdT) enzyme that adds desired base pairs without compromising purity or desired structural integrity of the synthetic DNA chain.
Steve Bischoff, founder and CSO of NovoHelix, was looking to make some difficult CRISPR knock-in sequences, incorporating lox sites and Cas9-targeting sequences for site-specific recombination. With chemical synthesis, he noted that complex G+C-rich sequences may come back “riddled with indels.”
Biscoff told Nature Biotech, “Those sites have inverted repeats with a spacer, and based on the topology of the oligo, it’s challenging to synthesize because of the three-dimensional folding structure.” Bischoff added that the oligos from Molecular Assemblies were sequence-perfect, allowing him to expedite his experiments, ensuring they were right the first time.
Molecular Assemblies FES technology delivers without compromising oligonucleotide length, purity, or accuracy. Learn more about getting access to the FES technology by visiting: https://molecularassemblies.com/now-available.